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 1 
Background 
 
Approximately 660,000 Americans are being treated for kidney failure or end stage renal 
disease (ESRD) annually [1]. There are also a variety of additional diseases and injuries such as 
cancer, direct impact burns, sickle cell anemia and urinary tract infections that cause kidney 
problems, adding to the number of patients who require dialysis [1]. The greatest need for 
dialysis, is chronic kidney disease, which affects nearly 14% of the human population [2]. 
Dialysis is necessary, yet it is extremely costly and significantly decreases the quality of life 
often leading to other diseases such as hypertension, anemia, and vascular calcification [3]. In 
fact, nearly half of hemodialysis deaths are due to cardiovascular issues that are often a side 
effect caused by the treatments [3]. Dialysis is also expensive, costing the United States an 
annual $49 billion and an American patient an average annual out of pocket cost of $89,000 [3, 
4]. 
Dialysis is needed when one’s kidneys are unable to function fully to remove wastes 
from the blood that is often due to kidney failure or other complications [5]. A patient can 
undergo hemodialysis or peritoneal dialysis and the decision is based on patient motivation, 
desire, geographic location, or physician and patient education [6]. Peritoneal dialysis is not 
used as often as hemodialysis is in the United States. The process of peritoneal dialysis is 
through the use of a catheter, a plastic tube that is placed into one’s body through surgery. A 
cleansing fluid is brought into the stomach through the catheter and removed through the same 
catheter once the filtering processing is complete [7]. The use of peritoneal dialysis has 
declined over the past 15 years due to a lack of education and exposure by physicians, so, 
hemodialysis is the most common choice [8].  
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Most hemodialysis treatments occur about three times a week, and last between three to 
five hours each session [5]. Dialysis is completed through a dialysis machine and a filter called 
a dialyzer. The dialyzer acts as an artificial kidney that is responsible for cleaning and filtering 
the blood. To connect a patient to a dialysis machine, access points are made into the vein 
through two needles, the arterial and the venous needle [9]. Blood is removed from the arterial 
line, as indicated in red, and returned through the venous line into the vein, as seen in blue (Fig. 
1).  
 
Figure 1: The basic process of filtering the blood through a dialysis machine. The blood is removed through the 
arterial line (red) and returned into the body through the venous line (blue) [10]. 
 
A patient is connected to a dialysis machine with butterfly needles to access the vein and 
the use of a catheter, fistula, or a graft. A catheter is most commonly used at first and over time, 
a fistula or graft would be the subsequent option [9]. A fistula is the first choice for hemodialysis 
because of its longevity and lowest association with morbidity and mortality [10]. There are 
often more infectious and thrombotic complications associated with grafts and catheters [11].  
Out of the 468,000 Americans who go on dialysis every year [12], 68% have an 
arteriovenous (AV) fistula (Fig. 2) [13]. In order to undergo dialysis, a patient needs a very high 
 3 
flow of blood localized to the site of the needle insertion, which does not exist until the blood 
vessels are manipulated. The most effective way this is done, is by performing a surgery to 
connect an artery to a vein. This connection is known as an AV fistula. The AV fistula allows 
blood from the artery to flow faster and at higher pressures through the vein, causing the vein to 
become larger and stronger [14]. Thus, the vein becomes suitable for insertion of the needles, 
that are needed to access the blood supply during treatment.  
 
Figure 2. Model of  how blood is circulated through the arm during hemodialysis treatment [15]. The needles are 
placed in the vein that has been enlarged by the fistula. The venous needle points towards the body to bring the 
blood back into the heart. The arterial needle points away from the body and brings the blood out of the vein to the 
dialysis machine [16]. 
 
One complication associated with a fistula and dialysis is access recirculation (AR). 
Access recirculation results from complications in the way the blood exits the arterial needle 
and returns into the vein through the venous needle (Fig. 3). The already dialyzed (cleaned) 
blood re-enters through the dialyzer and is cleaned again, while the rest of the patient’s blood is 
not cleaned [10]. AR causes a decrease in dialysis efficiency, since toxins are not properly 
removed from the blood [17]. AR can happen to any patient, varying from treatment to 
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treatment, as it is a problem with the current technology of two butterfly needles used during a 
dialysis procedure and not with the patient. Recirculation is often identified after treatment has 
begun, leading to an insufficient dialysis treatment. Since treatment is often too far along, it 
cannot be corrected once it has been identified. Once dialysis has begun, it cannot be abruptly 
stopped once recirculation has been identified. The blood that has been removed must have 
significant time to return to the patient’s body. 
 
Figure 3. The process of recirculation occurs when blood recently cleaned by the dialyzer is recirculated through the 
arterial line (red), rather than passing through the circuit of the venous side [18]. The normal flow of the blood, or 
access flow, is towards the heart, since the blood is flowing through the vein. The abnormal blood, or recirculated 
blood, is traveling in the opposite direction of the normal blood flow. The recirculated blood is able to flow in the 
opposite direction of the normal blood flow because of different pressures and flow mechanics.  
 
The most common cause of recirculation is when the needles are incorrectly placed, 
since they are often placed too close together. There are proper parameters that specify how to 
place the needles during a dialysis treatment to limit recirculation from occurring. Nurses often 
overlook the parameters and there is no current technology in place to ensure proper placement. 
These parameters include placing the needles 5 cm apart and placing the needle into the vein at 
a 20 to 35 degree angle [19].  
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There is no current technology to prevent access recirculation (AR), however, a method 
of guiding a needle into a blood vessel has been patented. The needle insertion guide apparatus 
is attached to the patient’s arm and uses a transducer array to locate the intended blood vessel. 
Once the needle is positioned on the apparatus, it moves according to the transducer to ensure 
appropriate access to the blood vessel [20].  
 
Figure 4. An apparatus to guide a needle into a blood vessel of a patient [20]. 
 
Problem Statement 
Access Recirculation (AR) severely decreases the efficiency of dialysis while having the 
potential to lead to a variety of complications (Fig. 3). If recirculation occurs during treatment, 
the patient may be at risk of developing stenosis (narrowing of blood vessels), leading to 
thrombosis (the local coagulation/clotting of blood) [4]. The most influential cause of 
recirculation results from the misplacement of the arterial and venous needles and will 
significantly harm the patient, wasting both money and resources. It is clear that the medical 
community has focused their energy on developing a proactive approach to monitoring AR, 
instead of preventing it. Creating biomedical devices that closely monitor the occurrence of AR 
isn’t sufficient enough. In order to prevent further complications and ensure dialysis is as 
efficient as it should be, the goal should be to eliminate AR. There is a clear need for a device 
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that can be implemented during hemodialysis treatments to reduce the percentage of recirculated 
blood, thusly reducing the occurrence of treatment for an individual and aiding the nurses in 
proper needle placement. 
Design Objectives  
 
In order to create a device to reduce or eliminate recirculation, certain objectives needed 
to be taken into consideration. We arrived at these objectives by analyzing the current method 
of dialysis and identifying flaws with the placement of the needles.  Our design is able to fulfill 
these objectives of usability, safety, effectiveness, and cost.  
To increase usability, our device must be lightweight and comfortable for the patient. 
The device should be small and reasonable to keep on the patient's arm for the entirety of 
treatment. It should also be organized and maneuverable for the nurse placing it. Since it is easy 
to use, the nurses should have no difficulty accessing the vein for dialysis. The maneuverability 
aspect of the device will allow a patient to lift their arm without impeding dialysis or the 
dislodging the needles. 
In order for our device to be as safe as possible, it must be durable, as any change in the 
morphology of the device during needle implementation could result in consequences for the 
patient. The needles must be secured to the arm since any unattended dislodgement during a 
treatment could result in the patient’s death within four minutes [21]. The device has to be safe 
for the needles entering the vein and be biocompatible on the surface of the arm. The device 
cannot cause the needle placement to result in an infection, clotting or disrupt the normal fistula 
blood flow rates of 0.6 to 1.5 L/min [22]. The needle should also cause no disruption of the 
vasculature on the backside of the vein, opposite of the insertion side.  
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To increase the effectiveness of our device, it must decrease the recirculated blood 
between the arterial and venous needles implemented during dialysis. Because of the current 
technology, the cost should be reasonable to ensure the device is implemented. Since there is 
currently no other device to eliminate recirculation, there will be no competition with other 
devices. The device is relatively small and should be easily produced on a wide scale.  
Device Functions and Specifications  
 
To further elaborate on the objectives of our device, we needed to determine which 
functions were essential. Success can be determined by meeting the standards of the set 
objectives. Eight major functions of our device were decided upon, and can be seen outlined in 
Table 1. The most important functions were ensuring the needles are placed at the proper 
distance apart from each other and at the appropriate angle. The most influential function would 
be eliminating confusion nurses have with needle implementation, as this is the main cause of 
why recirculation occurs.  
Table 1. Functions.  
1. The device safely rests on the skin.  
2. The device keeps the butterfly needles stable. 
3. The device keeps the proper distance between needles.  
4. The device keeps the proper angle between needles and the skin.  
5. The device ensures the needles maintain consistent venous outflow of blood and 
arterial inflow of blood.  
6. The device works with current butterfly needles.  
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7. The device ensures the needles enter the fistula correctly. 
8. The device eliminates confusion nurses have with its needle implementation.  
 
As our goal is not to completely reinvent a dialysis treatment, but instead redesign a 
certain portion of it. Our design must meet certain specifications put in place by current 
technology. For these functions to be implemented correctly into our device, current 
specifications must be met or improved upon. Specifications can be seen in Table 2. The most 
important specifications would be to place the needles 5 to 7 cm apart and at an angle of 20 to 
35 degrees between the needle and the skin. The most influential specification would be 
ensuring the red and blue colors for the arterial and venous needles, respectively, are labeled 
appropriately to ensure the nurses do not place the needles incorrectly.  
Table 2. Specifications.  
1. The material will be PLA, ABS, or another biocompatible plastic [23]. 
2. The device keeps the entire needle inserted during the full period of dialysis treatment.  
3. The needles need to be placed 5 to 7 cm apart [23]. 
4. There must be an angle of 20 to 35˚C between the needle and the skin [19].  
5. Extracorporeal blood flow rate (QB) for children of 150 to 200 mL min−1 m−2 and 
for adults extracorporeal blood flow rate (QB) of 200–400 mL min−1 m−2, 
with an initial rate no less than 400 mL min-1 m-2 [25].  
6. The device must work with butterfly needles 14 to 16 gauges [24].  
7. The entire needle must enter the fistula without penetrating the other side of the 
vasculature [19].  
8. The ends of the device which hold the needles during treatment will be color coded so 
the nurses place the correct needles in the proper ends of the vasculature. The arterial 
side will be colored red and the venous side will be colored blue.  
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Design Requirements  
The main goal for our design has been to eliminate recirculation during dialysis. 
According to the literature, if the distance of the two needles is 5 cm apart and the angle of 
insertion is between 20 to 35 degrees, no recirculation will occur [19]. If our device resolves 
these issues, our secondary focus is needle placement and ensuring that the needles are securely 
positioned in the patient’s vein.  
The most important aspects of our AR prevention device include it being easily 
controllable by a nurse, efficient in preventing AR, and prohibit complications. The first 
requirement states that nurses must insert the arterial and venous needles at the proper distance 
from one another and in the proper orientation at least 80 to 85% of the time [26]. Many 
researchers agree that inadequate placement of the arterial and venous needles is the number one 
cause of AR during hemodialysis [26, 27, 4]. It is common for dialysis nurses to accidentally 
switch the venous and arterial lines, or place them at the incorrect distance from one another, 
both of which significantly increase recirculation. Schneditz found that 25% of hemodialysis 
patients originally had their needles incorrectly placed [26]. While improper training of medical 
staff can be attributed to this issue, a device that does not allow the opportunity for this issue to 
initially arise is crucial. 
Another requirement is the device must reduce the percentage of recirculated blood 
during a hemodialysis treatment [4]. When designing the product, the percentage of recirculated 
blood will be tested by ensuring the proper distance apart and angle of the needles is correct. The 
percentage of recirculated blood can be determined to see if the blood was properly cleaned and 
the toxins were removed. When the finished device is applied to real treatments, the percentage 
of recirculated blood will be measured using one of the current methods, such as the urea 
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concentration method. While keeping a low rate of recirculated blood is crucial for decreasing 
the cost and length of each specific treatment, it is also very important to consider the safety of 
the patient. A high rate of AR could lead to further complications, such as thrombosis or cardiac 
conditions, either during, or shortly after treatment [4]. It is also our hope that by increasing the 
efficiency of treatment, the length of treatment will decrease. While conceptually the decrease of 
treatment duration makes sense, there is no research to help enforce our prediction, so, modeling 
of this system will be extremely necessary. Therefore, in order for the device to reach its full 
potential in regard to its effectiveness, it must limit the recirculation of blood. 
Although the purpose of the device is not to improve the safety of dialysis treatment, it is 
crucial that the device does not introduce new health risks to the patient during treatment. In 
order for the current safety requirements to be maintained, an extracorporeal blood flow rate of 
150 to 200   
   ∗ 2 must be preserved [Eqn. 2] [25]. Extracorporeal refers to outside the human 
body, or when the blood is in the needles, tubes, or dialyzer. It is important for the blood to 
remain in this range of values throughout the treatment, in order for the treatment to be effective 
and to prevent an accelerated risk of thrombosis, hypotension, or other side effects of 
hemodialysis [25]. It should also be noted that it is quite common for patients on hemodialysis to 
contract infections, due to their weakened immune system and exposed bloodstream [28]. 
Second to cardiovascular disease, infections are the next leading cause of death among 
hemodialysis patients resulting in 9.6% of these deaths among patients [30].  
 Documentation of Proposed Design 
Our proposed design is the Cannulation Pilot (Fig. 5) and it is responsible for reducing 
recirculation during dialysis. The inspiration for the device originates from the butterfly needles 
used to access the vein in dialysis. It was constructed through the program SolidWorks and 3D 
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printed as one singular piece of material. The external device is placed on the surface of the 
patient’s arm and held to the skin using an electrode. This device gives nurses a guide for 
needle insertion into the vein. The indent in the device allows a butterfly needle to rest securely 
and the tape is used over the top of the needles to prevent it from moving during treatment. The 
Cannulation Pilot will hold the butterfly needle at a 30 degree angle when accessing the vein for 
treatment.   
 
Figure 5. Cannulation Pilot with Needle and Injection Pad. The butterfly needle is placed into the device and held 
at a 30 degree angle during treatment. It will rest on the surface of the patient’s skin and prevent recirculation from 
occurring.  
 
The Cannulation Pilot is composed of two butterfly pilots. The two butterfly pilots will 
face in opposite directions from each other and connect in the middle. The flexibility of the 
central connection allows for the device to maneuver and fit to various fistulas. To limit 
recirculation, the needles must access the vein at an angle of 20 to 35 degrees and a distance of 
5 to 7 cm apart [19]. Since the Cannulation Pilot is responsible for holding the needles at a 30 
degree angle and at a fixed distance of 6.5 cm apart from each other, no recirculation should 
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occur. In order to discriminate between the arterial needle and venous needle, the pilots will be 
red and blue, respectively (Fig. 5).  
The needles will slide over the pilots as they enter the vasculature and are placed in to 
maintain stability during treatment, limiting the use of unnecessary and irritating cotton balls. 
The pilots will be held down by a double sided biocompatible adhesive. The current adhesive 
used is an electrode and will change if a more efficient adhesive is made aware of. Because the 
device is so small and relatively cheap to make, it will be a disposable device after one use. The 
material currently used for the Cannulation Pilot is a flexible TPE material. The flexible 
material was used to bend to various fistula shapes and sizes.  
Validation of the Design   
 While we have no way of testing the exact amount of recirculated blood prevented using 
our device due to restrictions in equipment and time, simply placing the needles at the correct 
distance and angle will reduce AR [19]. In order to validate the success of our device, we will 
test the parameters hold true regardless of the environment where the device is placed. To 
evaluate the functions of the Cannulation Pilot, five tests will be performed. The tests include 
measuring the stability of the device, the consistency in defining the distance between both 
access points, the accuracy in ensuring the correct angle of the needle insertion, the adaptation to 
various fistulas and the “stickiness” of the device. 
 To test the device’s stability, an orbital shaker will be used. We will insert the needles 
into an injection pad using our device and place it on the shaker. The orbital shaker will agitate 
the system, providing disturbances to the needles and the device. We will “shake” the system for 
five minutes and observe any disturbances. This will be done a total of five trials. If the needles 
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slip or are moved in any way, we will need to adjust the device. This test is meant to represent 
the the patients moving during treatment.  
 In order to evaluate the distance between the access points, we will insert the needles into 
the injection pad using our device for 10 trials. Since the connection between the two pilots of 
our device is flexible, we will bend it to the greatest degree possible in some trials, while keeping 
it unbent in others. For each trial, we will use a ruler to measure the direct distance between the 
two insertion points. While it is understood that this number may not be ideally consistent due to 
the bending of our device, the total distances must be between an acceptable range of 5 cm and 7 
cm. 
 Similarly to the evaluation of the proper distance of the needle placement, the test for the 
proper needle angle will also involve inserting the arterial and venous needles into the injection 
pad with our device and the current method. The current method involves angling the needle 
with cotton balls and securing it with tape. We will insert the needles into the injection pad ten 
times for each system and photograph the profile of each placement. Using the photographs, we 
will measure the insertion angle of each trial. Our device must accurately depict the ideal 
injection angle of 20 to 35 degrees and be consistent for all ten trials. We will compare the 
results from the placements using our device with the results of the placements using the current 
method. In order for AR to be reduced, the angle of injection must be both accurate and precise 
and exist within the range of 20 to 35 degrees. 
 Fistulas arise in a variety of unpredictable shapes and sizes. In order for our device to be 
universally effective, it must adapt to each one. As a result, the middle connection of our device 
will be morphable. We will cut portions of the foam out of the silicone-foam injection pads to 
mimic the shape of five fistulas, purposely creating ones that are excessively big or oddly 
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shaped. In order to move forward with our device, it is necessary that it can be manipulated to fit 
onto each fistula without resistance or the tendency to “bend back” into its original structure.  
 The results of our validation tests supported the success of the Cannulation Pilot (Table 
2). Although the average distance for the distance test for both the needle method and the cotton 
ball method were within the 5 to 7 cm range, the results were biased since the experimenters had 
a ruler to reference the proper distance. The angle test for the needle method was below the ideal 
angle and the cotton ball method was above the ideal angle of 20 to 35 degrees. For both the 
distance and angle tests, the Cannulation Pilot was successful. The various fistulas test and the 
shaker test was successful for all three methods. The inversion test was unsuccessful for the 
current cotton ball method since the needles did not remain in the patient’s arm. Our device, 
however, kept the needles secure. The Cannulation Pilot could ensure more patient movement 
throughout treatment without the movement of needles.  
Table 3. Validation tests results.  
 
 Dialysis treatment typically lasts four hours and it is necessary that our device will not 
fall off or move for the entirety of the treatment. The external pressure on the two needles could 
be unsafe for the patient. In order to prevent this, our device will stick to the patient by attaching 
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electrode-like layers to the bottom of the pilots. In order to evaluate the “stickiness,” we will 
stick the device to an injection pad and invert it. The inversion will be held for five minutes and 
will be performed five times. If the device falls or moves on the injection pad during the five 
minute time span, we will need to adjust our mechanism. Although dialysis treatment is typically 
four hours, the inversion will accurately assess our device. 
Anticipated Regulatory Pathway 
Venous dislodgement during dialysis can be life-threatening. To prevent any risk of 
venous needle dislodgement during treatment, the needles and lines need to be properly taped. 
There are several different types of medical tape that exist, however, the most common type that 
is used specifically for anchoring the needles during dialysis is Micropore [31]. Other predicate 
devices such as silk, paper, or transparent medical tape may be used if a patient is allergic to 
Micropore. An example of Micropore is the Microporous Medical Adhesive Tape. The 
Microporous Medical Adhesive Tape is a breathable tape with both a porous backing layer in 
addition to a microporous adhesive layer [32]. The nurses are required to use this medical tape to 
secure the needles to the patient’s arm. The needles must be secured in place to prevent 
accidental dislodgement or movement of the needles after they have been accessed. If the tape is 
improperly used and the needles move within the fistula, poor blood flow or needle infiltration 
may be a result [19]. According to the FDA, the decision of the Microporous Medical Adhesive 
Tape was “Substantially Equivalent (SESE)” [33] The device was deemed as safe and effective 
as the predicate.  
Table 4. Analysis of 510(k) premarket notification [33].  
Device Name Microporous Medical Adhesive Tape 
510(k) number K840447 
Applicant Lectec Corporation  
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Classification Product Code  KGX 
Regulation Description Medical adhesive tape and adhesive banda 
Review Panel General Hospital 
Regulation Number  880.5240 
 
The differences that the Cannulation Pilot might encounter in comparison to the FDA 
cleared device, the Microporous Medical Adhesive Tape, would be ensuring the safety and the 
biocompatibility of the pilot component itself. Although the electrodes are used to keep the device 
attached to the patient’s arm, it must be ensured that the device will not cause any harm to the 
patient. Since there is no device similar to the Cannulation Pilot itself, the process of approval 
from the FDA may not be as simple as a substantial equivalence. Moving forward, the Cannulatin 
Pilot would need to be made out of a biocompatible material to ensure the safety of the dialysis 
patients.  
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Appendix A 
 
AMC Visit Notes 
 
I. AMC visit 
A. Thursday, January 17th under supervision of Dr. Smith 
B. We took a rough prototype of the cannulation platform with us to AMC. The 
rough prototype was to allow the nurses to better understand our device and to 
better conceptualize how our device would fit on a patient. The purpose of this 
visit was mainly to gather suggestions about modifications to the device.  
C. We had a list of questions we came up with in class that day to make sure we 
asked the nurses about  
1. Curvature and location of vein 
2. Visual - device being transparent 
3. Needle security - straps for the device  
4. Hole size and placement (algorithm) 
5. Children vs. adults 
II. AMC discussions 
A. We started off by explaining our capstone project and how we are trying to build 
a device to help eliminate recirculation from occurring during dialysis. We 
showed them our design and one of the nurses placed it on her arm. We asked 
them all our questions in regards to our device. We learned the fistula may not be 
on the lower arm and is often placed on the upper arm. The fistula may be 
different shapes (not universal) and depends on how vascular surgeon performs 
surgery. They liked the comfort aspect of the padding on the straps and the 
adjustability to account from arm swelling. The problem with the strap would be 
patients removing it during treatment. 
B. Discussion with Dr. Monrroy  
1. We explained our design and he told us the rule of maturation for a fistula 
is 6mm wide/long/deep. He told us to avoid the devices in the vein and to 
stay on the surface to avoid thrombosis problems. The main issue we 
learned was finding the fistula, especially in patients who are obese. We 
visited three different patients to see and feel their fistulas. We learned 
that our device wasn’t going to work. Our ideas were going in the right 
direction and needed to be modified.  
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Appendix B 
 
Evolution of Previous Designs  
 
 
Figure 6. Our first design started off as a simple rectangular shape. With trial and error, we started to use less 
material and change the shape. The final prototype was inspired by the butterfly needle used for dialysis.  
 
 
 
Figure 7. Our 3D printed prototypes were created by outlining the edges of the butterfly needle. The device evolved 
from two seperate pilots connected by a flexible wire to one singular device.  
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Appendix C 
Helpful Materials 
 
Material Price 
Medical Tape $8.99 
Velcro $4.91 
Needle Injection Pad $25.99 
16 Gauge Needles $9.32 
Butterfly Needles $40.22 
Silicone and Sponge Injection Pad X2 $27.98 
Electrodes  $8.85 
Double Sided Foam Tape  $7.99 
X-Acto Knife  $7.31 
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Appendix D 
Validation 1: Shaker Test  
 
Validation 2: Distance Test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Validation 3: Angle Test  
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Appendix E 
Validation 4: Various Fistulas Test 
Fistula 1: 
 
Fistula 2:  
 
 
 
Validation 5: Inversion Test  
 
